GENSCRIPT BIO (01548) experienced a sharp decline of over 7%. At the time of writing, the stock was down 6.98%, trading at HKD 13.07 with a turnover of HKD 130 million. The drop is linked to a significant overnight plunge of more than 11% in the share price of its affiliate, Legend Biotech. On the evening of January 21, GENSCRIPT BIO announced that Legend Biotech disclosed CARVYKTI's net trade sales for the fourth quarter ended December 31 of the previous year were approximately USD 555 million. The group stated that the net trade sales figure was based on information provided by Janssen to Legend, and neither Legend nor the group has independently verified the accuracy of the sales number. It is understood that CARVYKTI achieved sales of USD 1.332 billion in the first three quarters, with third-quarter sales amounting to USD 524 million.
Comments